Original
Seguridad del empleo de regadenosón como fármaco vasodilatador en resonancia magnética cardíaca de estrés
Safety of regadenoson for vasodilation in cardiac MRI stress tests
Leído
1832
Vecesse ha leído el artículo
303
Total PDF
1529
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 12 | 5 | 0 | 5 |
| 2025 11 | 0 | 6 | 6 |
| 2025 10 | 64 | 14 | 78 |
| 2025 9 | 65 | 9 | 74 |
| 2025 8 | 55 | 2 | 57 |
| 2025 7 | 49 | 2 | 51 |
| 2025 6 | 49 | 3 | 52 |
| 2025 5 | 89 | 6 | 95 |
| 2025 4 | 65 | 5 | 70 |
| 2025 3 | 74 | 2 | 76 |
| 2025 2 | 107 | 8 | 115 |
| 2025 1 | 72 | 10 | 82 |
| 2024 12 | 35 | 4 | 39 |
| 2024 11 | 26 | 1 | 27 |
| 2024 10 | 29 | 0 | 29 |
| 2024 9 | 24 | 0 | 24 |
| 2024 8 | 5 | 0 | 5 |
| 2024 7 | 13 | 2 | 15 |
| 2024 6 | 35 | 16 | 51 |
| 2024 5 | 16 | 1 | 17 |
| 2024 4 | 17 | 0 | 17 |
| 2024 3 | 28 | 4 | 32 |
| 2024 2 | 15 | 0 | 15 |
| 2024 1 | 29 | 2 | 31 |
| 2023 12 | 27 | 0 | 27 |
| 2023 11 | 32 | 10 | 42 |
| 2023 10 | 62 | 0 | 62 |
| 2023 9 | 10 | 2 | 12 |
| 2023 8 | 15 | 0 | 15 |
| 2023 7 | 16 | 0 | 16 |
| 2023 6 | 20 | 2 | 22 |
| 2023 5 | 38 | 2 | 40 |
| 2023 4 | 24 | 0 | 24 |
| 2023 3 | 32 | 13 | 45 |
| 2023 2 | 31 | 0 | 31 |
| 2022 1 | 17 | 2 | 19 |
| 2022 12 | 7 | 0 | 7 |
| 2022 11 | 11 | 5 | 16 |
| 2022 10 | 4 | 6 | 10 |
| 2022 6 | 1 | 2 | 3 |
| 2022 4 | 1 | 2 | 3 |
| 2022 3 | 4 | 3 | 7 |
| 2022 2 | 2 | 3 | 5 |
| 2021 1 | 1 | 2 | 3 |
| 2021 12 | 1 | 2 | 3 |
| 2021 11 | 18 | 6 | 24 |
| 2021 10 | 1 | 1 | 2 |
| 2021 6 | 1 | 2 | 3 |
| 2021 5 | 1 | 4 | 5 |
| 2021 4 | 3 | 6 | 9 |
| 2021 3 | 1 | 2 | 3 |
| 2021 2 | 1 | 0 | 1 |
| 2020 1 | 5 | 4 | 9 |
| 2020 12 | 79 | 16 | 95 |
| 2020 11 | 7 | 9 | 16 |
| 2020 10 | 16 | 6 | 22 |
| 2020 9 | 9 | 5 | 14 |
| 2020 8 | 1 | 0 | 1 |
| 2020 7 | 4 | 2 | 6 |
| 2020 6 | 29 | 10 | 39 |
| 2020 5 | 31 | 47 | 78 |
| 2020 4 | 0 | 4 | 4 |
| 2020 3 | 0 | 4 | 4 |
| 2020 2 | 0 | 6 | 6 |
| 2020 1 | 0 | 16 | 16 |
Mostrar todo
